CN1138298A - 疫苗 - Google Patents

疫苗 Download PDF

Info

Publication number
CN1138298A
CN1138298A CN94194554A CN94194554A CN1138298A CN 1138298 A CN1138298 A CN 1138298A CN 94194554 A CN94194554 A CN 94194554A CN 94194554 A CN94194554 A CN 94194554A CN 1138298 A CN1138298 A CN 1138298A
Authority
CN
China
Prior art keywords
mpl
antigen
virus
vaccine
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN94194554A
Other languages
English (en)
Other versions
CN1086589C (zh
Inventor
帕特里夏·M·莫米恩
内森里·M-J·加肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1138298A publication Critical patent/CN1138298A/zh
Application granted granted Critical
Publication of CN1086589C publication Critical patent/CN1086589C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

本发明提供了疫苗组合物，含有一种水包油乳液，该乳液可任选地与3-脱氧酰基化单磷酰脂A和QS21相组合。该疫苗组合物是许多免疫应答的强有力的诱导剂。

Description

疫苗
本发明涉及新的疫苗制剂，及其生产方法以及该疫苗制剂在医学上的应用。特别是，本发明涉及一种水包油乳液。这种乳液包括生育酚、角鲨烯、吐温80、Span 85(司盘85)以及卵磷脂，并且具有有效的佐剂特性。含有一种来源于Quillaja Saponaria Molina的树皮的HPLC纯化的非毒性组分，QS21，和/或3脱氧酰基化的单磷酰脂A(3De-O-acylated monophosphoryl lipid A，3D-MPL)，以及这样的水包油乳液进行组合的疫苗也是本发明的一部分。
从GB 2220211(Ribi)知道了3脱氧酰基化的单磷酰脂A。从化学上说，它是一种具有4，5或6酰基化的链的3脱氧酰基化的单磷酰脂A的混合物，由Ribi Immunochem Montana制备。在国际专利申请NO.92/116556中公开了3脱氧酰基化的单磷酰脂A的一种优选形式。
QS21是一种来自南美的Quillaja Saponana Molina树的树皮的经Hplc纯化的皂角苷(Saponin)的非毒性组分，其生产方法公开(以QA 21形式)于美国专利NO.5,057,540中。
水包油乳液本身是现有技术中已知的，并且已有人建议可将其用作为佐剂组合物(EPO 399843)。
本发明是基于下列惊人发现，与现有技术的乳液不相同的本发明的水包油乳液，含有生育酚或者含有结合了QS21和/或3D-MPL的生育酚，从而增强了对给定抗原的免疫应答。这种增强作用比迄今为止以前的所有同类制剂能提供更好的免疫应答。
另外，当将本发明的水包油乳液与3D-MPL和QS21一起配制时是IgG2a产生和TH1细胞应答的优选的刺激剂。这是有利的，因为在细胞介导的应答中已知包含有TH1应答。的确在鼠中IgG2a的诱导是与这样一种免疫应答相关的。
例如以这种方式组合的HIV抗原gp120的疫苗制剂可强有力地增效诱导对gp120蛋白质的特异的免疫应答。
观察到可能诱导强的细胞溶解的T淋巴细胞应答的结果很有意义，因为在一些动物模型中已经证明这种细胞应答诱导了抵抗疾病的保护作用。
本发明人已经证明，佐剂QS21和3D-MPL以及在一起的水包油乳液与一种抗原结合后在脾脏中导致对CS蛋白质特异性的CTL的强力诱导作用。QS21本身也增强了CTL的诱导，而3D-MPL不能。
当胞内合成靶抗原时(例如由病毒，胞内细菌产生的感染，或在肿瘤中)容易看到CTL的诱导作用，因为由抗原的蛋白质裂解产生的肽可以进入合适的加工途径，导致以与I类分子相结合形式呈现在细胞膜上。但是，一般来说，预形成的可溶性抗原没有到达该加工和呈现途径，并且没有诱导I类范围内的CTL。因此，可诱导抗体和T辅助应答的常规的非活性疫苗一般不能诱导CTL介导的免疫应答。两种佐剂QS21和3D-MPL与水包油乳液结合在一起能够克服基于重组蛋白质的疫苗的严重的局限性，并可诱导更宽范围的免疫应答。
已经证明在鼠模型系统中特异于CS蛋白质的CTL可抵抗疟疾(Romero等人，Nature 341：323(1989))。在人试验中，当将志愿者用恶性疟原虫的被辐射过的子孢子体进行免疫接种后，可显示出抵抗随后的疟疾的进攻，显示出诱导出了特异于CS表面抗原决定簇的CTL(Malik et al. Proc. Natl. Acad. Sci.USA 88：3300(1991))。
可诱导出对以重组分子形式给药的一种抗原具特异性的CTL的能力是与疟疾疫苗的研制相关的，因为基于免疫应答的产生及其特性，使用经辐射的子孢子体是不切实际的。
RTS是一种杂合蛋白质，它基本上含有借助于乙肝表面抗原的pre S2部分的四个氨基酸连接到乙肝病毒的表面(S)抗原上的恶性疟原虫的环子孢子体(CS)蛋白质的整个C末端部分。其完整结构公开于共同待批国际专利申请NO.PCT/EP 92/02591，该申请要求了UK专利申请NO.9124390.7的优先权，其公开号为WO 93/10152。当在酵母中表达时产生出脂蛋白颗粒形式的RTS，并且当以与HBV的S抗原共表达时产生出已知为RTS，S的混合颗粒。
除了人免疫缺陷病毒和疟疾疫苗外，诱导CTL应答的能力有利于抗单纯性疱疹病毒，巨细胞病毒以及通常的具有胞内生活期的病原体的所有病例的疫苗。
同样，将重组肿瘤抗原和两种佐剂组合后可诱导特异于已知肿肿瘤抗原的CTL。这为研制抗癌疫苗提供了条件。
在一些系统中，将3D-MPL和QS21以及水包油乳液结合起来能够协同地增强干扰素γ的产生。本发明人利用已知的名为gD2t的单纯性疱疹抗原证明了3D-MPL和QS21与水包油乳液组合在一起的潜力。gD2t是一种从HSV-2上切下的可溶性糖蛋白D，并且是采用Berman等人的方法(Science 222 524-527)在CHO细胞中产生的。
IFN-γ的分泌是与抗胞内病原体，包括寄生虫，细菌和病原体的保护性应答相关的。由IFN-γ对巨噬细胞的激活增强了胞内对微生物的杀伤力以及增强Fc受体的表达。也可能存在直接的细胞毒性，尤其是在与淋巴毒素(TH1细胞的另一种产物)进行增效作用时。IFN-γ既是NK细胞的诱导剂又是其产物，NK细胞是保护作用的主要的固有的效应子。通过IFN-γ或者其他机制进行的TH1型应答为IgG2a免疫球蛋白同型提供了优先帮助。
糖蛋白D定位于病毒包膜上，并且也存在于受感染细胞的胞质中(Eisenberg R.J.等人J.of Virol.1980 35：428-435)。它含有包括信号肽在内的393个氨基酸并且具有约60KD的分子量。在所有的HSV包膜糖蛋白中，它可能是得到最详细表征的一种(Cohen等人，J.Virology 60：157-166)。已知在体内它对于病毒粘附到细胞膜上起着关键的作用。而且，已证明糖蛋白能够在体内诱导出中和抗体(Eing等人，J.Med.Virology 127：59-65)。但是，尽管在患者血清中存在高效价的中和抗体，潜伏的HSV2病毒仍能被重新激活并诱导疾病复发。因此，显然仅具有诱导中和抗体的能力不足于控制疾病。
为了防止疾病复发，任何疫苗需要不仅刺激中和抗体，而且激发由T细胞，特别是毒性T细胞介导的细胞免疫作用。
对于gD2t例子，它是308个氨基酸的HSV2糖蛋白D，它含有天然存在的糖蛋白的第1-306个氨基酸，在该被截短的蛋白质的C-末端添加了天冬酰胺和容氨酰胺。这种蛋白质形式包括信号肽，将该信号肽裂解后产生成熟的283氨基酸蛋白质。在Genentech的欧洲专利EP-B-139 417中已描述了在中国仓鼠卵细胞中生产这样一种蛋白质。
该成熟的被截短的糖蛋白D(rgD2t)或从哺乳动物细胞中分泌的等同蛋白质优先用于本发明的疫苗制剂中。
在患有生殖器疱疹的豚鼠模型中本发明的制剂可十分有效地诱导保护性免疫作用。甚至在具有非常低剂量抗原(例如低至5μgrgD2t)时该制剂可保护豚鼠抵抗初次感染，并且也激发了特异性的中和抗体应答。本发明人利用本发明的制剂也证实了在鼠中效应细胞介导的TH1型应答。
因此，在一个优选实施方案中，本发明提供了一种含有与3-脱氧酰基化的单磷酰脂A，QS21和一种水包油乳液相组合的抗原的疫苗或药物制剂，该水包油乳液含有一种可代谢的油，例如角鲨烯，α-生育酚和吐温80。这样一种制剂适合于很多的单价或多价疫苗。另外，该水包油乳液可含有span 85。3-脱氧酰基化的单磷酰脂A的一种优选形式公开于公开号为NO.92116556的Smithkline BeechamBiologicals s.a.的国际专利申请中。
该水包油乳液可以单独使用或与其他佐剂或免疫刺激剂结合起来使用，因此本发明的一个重要实施方案是一种含有角鲨烯或另一种可代谢油，α-生育酚和吐温80的水包油制剂。该水包油乳液还可含有span 85和/或卵磷脂。
优选的疫苗制剂含有能够引发抗人或动物病原体的免疫应答的抗原或抗原组合物，所述抗原或抗原组合物来源于HIV-1(例如gp120或gp160)，任何猫的免疫缺陷病毒，人或动物疱疹病毒，例如gD或其衍生物或立即早期蛋白如来源于HSV1或HSV2的ICP27，巨细胞病毒((尤其是人)(例如gB或其衍生物)，水痘带状疱疹病毒(例如gpI，II或III)，或者来源于例如已肝病毒的肝炎病毒，例如乙肝表面抗原或其衍生物，甲肝病毒，丙肝病毒和戊型肝炎病毒，或者来自于其他病毒病原体，例如呼吸道合胞体病毒，人乳头瘤病毒或流感病毒、或者来源于细菌病原体如沙门氏菌、奈瑟氏菌、螺旋体(例如OspA或OspB或其衍生物)，或者衣原体，或博德特氏菌例如P.69，PT和FHA，或来源于寄生虫如疟原虫或者弓形体。
该制剂还可含有一种抗肿瘤抗原并适用于采用免疫治疗法治疗癌症。
在一种适于免疫治疗的患有B细胞淋巴瘤的动物模型中，当在第0天时将BCL-1鼠淋巴瘤细胞静脉注射到Balb/c小鼠中，并在第3天，10天和20天用BCL-1同种异型给小鼠免疫接种，就抗体效价和存活率(该组为存活率为100％的唯一组)而言，SB62/MPL/QS21制剂被证明为最有效力。同样，该制激发针对所包含的抗原的细胞毒性T淋巴细胞的能力，使其成为作为癌抗原制剂的良好的候选物(例如用于通过活性免疫接种而对肿瘤进行免疫治疗的黑色素瘤抗原MAGE-1和MAGE-3)。
该制剂还适用于与疱疹的轻颗粒一起使用，例如描述于国际专利申请NO.PCT/GB 92/00824，以及国际专利申请NO.PCT/GB 92/00179的制剂。
乙肝表面抗原的衍生物是本领域内熟知的，并且特别包括那些在欧洲专利申请EP-A-414374；EP-A-0304578，和EP 198-474中描述的PreS1，PreS2 S抗原。在一个优选的方面，本发明的疫苗制剂包括HIV-1抗原，gp120，尤其是当在CHO细胞中表达时，在另一实施方案中，本发明的疫苗制剂包括如上文中定义的gD2t。
在本发明的又一方面，提供了如本发描述的在医学上使用的疫苗。
QS21与3D-MPL的比例通常是在1∶10至10∶1的范围，优选的是1∶5-5∶1并且实质上经常是1∶1。达到最适增效作用的优选范围是2.5∶1到1∶1的3D MPL∶QS21。当给人使用时通常疫苗中存在的QS21与3D MPL的比例为1μg-100μg/每剂量的范围，优选的是10μg-50μg/每剂量。水包油乳液通常含有2-10％的角鲨烯，2-10％α-生育酚以及0.3-3％吐温80。优选的是角鲨烯与α-生育酚的比例是等于或者低于1，因为这样使乳液更稳定。还可以存在1％含量的Span 85。在某些情况下，本发明的疫苗进一步含有一种稳定剂是有利的。
通常疫苗的制备可参见New Trends and Developments in Va-ccines，edited by Voller et al.，University Park Press，Baltimore，Maryland，U.S.A.1978。脂质体内进行包埋的方法例如可参见Fullerton，美国专利4,235,877的描述。蛋白质与大分子的结合例如公开于由Likhite的美国专利4,372,945以及Armor等人的美国专利4,474,757。
所选择单疫苗剂量中蛋白质的量为在典型的接种人中诱导产生免疫保护应答而无显著的毒副作用所需的量。该量将随所使用的特定免疫原以及如何提供而变化。通常，单个剂量含有1-1000μg的蛋白质，优选的是1-100μg，更优选的为4-40μg。采用包括观察个体中合适免疫应答的标准研究确定用于特定疫苗中的最适量。在首次免疫接种之后，受试个体可接受一次或者适当间隔的几次加强免疫接种。
本发明的药剂可用于预防和治疗目的。
因此，一方面，本发明提供了一种治疗方法，该方法包括给患者施用有效量的本发明的疫苗。
下面实施例阐明本发明。
                       实施例1
含有HIV-1的gp120抗原的疫苗制剂
制备两种佐剂制剂，每种含有下列水包油乳剂成分。
SB26：5％角鲨烯，5％生育酚，0.4％吐温80；颗粒大小是500nm。
SB62：5％角鲨烯，5％生育酚，2.0％吐温80；颗粒大小是180nm。
1(a)乳剂SB 62的制备(2倍浓缩)
将吐温80溶于磷酸缓冲盐水(PBS)中得到溶于PBS中的2％的溶液。为了提供100ml两倍浓缩乳液，将5克DLα生育酚和5ml角鲨烯涡流以便彻底混合。加入90ml PBS/吐温溶液并彻底混合。然后将得到的乳液通过一个注射器并且最后利用MllOS微射流机器进行微射流。得到的油滴具有约180nm的大小。
1(b)乳液SB26的制备
以类似的方式利用0.4％吐温80制备该乳液。
1(c)以类似的方式制备表1中描述的其他乳液。下列实施例中详细描述了检测这些乳液的试验。
1(d)gp120 QS21/3D MPL水包油制剂的制备
向1a)或b)或c)乳液中加入某体积的两倍浓缩的rgp 120(20μg或100μg)并且混合。将它与50μg/ml的3D-MPL和20μg/ml的QS21合并，得到最后的制剂。按照盐含量和pH值调整缓冲液。
表3显示利用来自HIV的gp120和50μg/ml 3D-MPL(MPL)以及20μg/ml的QS21的SB26的效果。结果显示在第二次(PII)和第三次(PIII)接种后效价的几何平均值(GMT)，以及对淋巴细胞增殖和γ干扰素产生作出的细胞介导的应答(CMI)。
                     实施例2
引言：一种HIV gp120乳液系统的评估
在该实验中，对四个乳液[SB26，SB62，SB40，SB61]进行比较。对各个制剂成分(抗原，乳液，3D-MPL，QS21)的效应进行评估。
2(b)所使用的动物试验组
使用22组，每组5个动物，使每组接受不同的疫苗制剂。
-1-4组：gp120(10μg)/无乳液±[3D-MPL，QS21]
-5-9组：gp120(10μg)/SB26±[3D-MPL，QS21]
-10组：无抗原/SB26+[3D-MPL，QS21]
-11-12组：gp120(10μg)/SB62±[3D-MPL，QS21]
-13-16组：gp120(10μg)/SB40±[3D-MPL，QS21]
-17-20组：gp120(10μg)/SB61±[3D-MPL，QS21]
-21-22组：gp120(5μg)/SB26±[3D-MPL，QS21]
-分析：抗gp120W61D的抗体效价以及同型分析(所有组)
2(c)免疫接种以及抽血时间表
-用gp120W61D对动物进行免疫接种，所述gp120W61D是配制于每剂量存在5μg 3D-MPL和5μg QS21的不同的油水乳液中。阴性对照接受没有抗原的等同制剂。
-在0和14天时皮下注射免疫接种动物。所给药的每次注射剂量为100μl。
-在免疫接种前(0天)以及在免疫接种之后第14天(第一次接种后)，第21以及28(第二次接种后第7和第14天)天获取血样品。
2(d)血清学应答分析：
-第一次接种后和第二次接种后的14天的血清学应答是采用针对gp120W61D的直接ELISA检测法进行评估的。
-用免疫接种之后小鼠中诱导出的gp120W61D特异性抗体的同型也对第二次接种后14天的应答进行表征。
3.结果和讨论
结果描绘于表2中。
a)在存在或不存在3D-MPL/QS21的乳液的比较：
-将SB26，SB40或SB62乳液加入到抗原中诱导出更高的抗体效价。在没有免疫刺激剂情况下，gp120特异性抗体基本上是IgG1。
-加入免疫刺激剂3D-MPL和QS21诱导了巨大的血清学应答并且抗体从IgG1型转变为IgG2a/IgG2b：这与细胞介导的免疫相关。
优选的组合是[SB26+MPL+QS21]。
c)gp120/SB26制剂：
在8组和9组之间没有观察到血清学应答之间的显著差异：在本制剂其他成分之前或之后加入gp120。
d)抗原剂量：
配制于SB26中的5和10μg gp120诱导了高血清应答(5-8组以及21-22组)。
                         实施例3
HSV rgD2t制剂
按照实施例1(a)中提出的类似方式，制备含有单纯疱疹抗原rgD2t的制剂并用于免疫接种豚鼠。所述制剂诱导出抵抗豚鼠模型中复发和起始疾病的保护作用。
                        实施例4
利用个体基因型作为免疫原筛查用于诱导保护性抗淋巴瘤应答的佐剂。
利用来自BCL1淋巴瘤细胞的个体基因型给Balb/c小鼠进行治疗性免疫接种。
由Yefenoh等人对BALB/C B细胞淋巴瘤模型进行了综述。Curr-ent opinions Immunobiology 1993 5：740-744。
用104肿瘤细胞在0天时注射(ip)的10只小鼠的组，并用溶于不同佐剂制剂中的100μg的KLH偶合的抗BCL1抗原决定簇的免疫球蛋白(KLH/Ig：1/1的比例)在第3天，10天，20天免疫接种(在背部皮下注射)。对抗KLH和抗个体基因型的血清抗体水平以及鼠死亡率进行了监测。
所检测的制剂：
组号      佐剂                 MPL：10μg
1         无(无抗原)           QS21：10μg
2         无
3         弗氏佐剂
4         明矾
5         明矾/MPL
6         明矾/MPL/QS21
7         QS21
8         MPL/QS21
9             SB62 MPL
10            SB62/MPL/QS21
12-15组：没有抗原的不同佐剂
与其他组相比，制剂8、9、10的行为均较好。在抗体效价以及存活率两方面，制剂10表现为最有效力(生存率为100％的唯一组)。
                      实施例5
RTS，S的不同制剂
a)在猴中的评价
在国际专利申请No.WO 93/10152中描述了RTS，S并且制成制剂用于给Rheusus免疫接种。每组有5个动物：
I组         RTS，S，3D-MPL(50μ)，Al(OH)3
II组        RTS，S，QS21(20μ)，Al(OH)3
III组       RTS，S，3D-MPL(50μ)，QS21(20μ)
IV组        RTS，S，3D-MPL(50μ)，QS21 Al(OH)3
V组         RTS，S，3D-MPL(10μ)，QS21 Al(OH)3
VI组        RTS，S，3D-MPL(50μ)，QS21 SB60
给动物接种并且在第一次免疫接种之后14天以及第二次免疫接种之后12天取血，并检测其抗乙肝表面免疫球蛋白。如在图1中可看到的，接受SB60中的RTS，S的动物具有的抗体效价几乎比任何其他组高出6倍。
b)用小鼠对RTS，S的各种制剂进行评估
7组动物接受下列制剂
1组            RTS，S SB26
2组            RTS，S QS21 3D-MPL
3组    RTS，S QS21 3D-MPL SB62
4组    RTS，S 3D-MPL Al(OH)3
5组    RTS，S Al(OH)3
6组    空白
7组    阴性对照
(RTS，S-5μg/剂量，3D-MPL 5μg/剂量，QS21 5μg/剂量)
给动物接种并且在第一次接种后15天以及在第二次接种之后7天和15天取血，并检测抗HBSAg抗体亚型。如在图2中可看到的，用QS21和3D-MPL配制的乳液SB62优先地和以协同增效方式加强IgG2a抗体应答，而单独的SB62或3D-MPL/QS21诱导极少的IgG2a应答。
实施例6：对不同的B burgdorferi OspA制剂的评估
6.1不同的B burgdorferi ZS7 OspA脂蛋白制剂的评估
在欧洲专利申请0418 827(Max Plank et al)中描述了B bur-gdorferi的OspA脂蛋白。
在balb/c鼠中检测下列制剂
1.OspA+Al(OH)3
2.OspA+Al(OH)3+3D-MPL(10μ)
3.OspA+Al(OH)3+3D-MPL(30μ)
4.OspA+Al(OH)3+3D-MPL(10μ)+QS21(5μ)
5.OspA+Al(OH)3+3D-MPL(30μ)+QS21(15μ)
6.OspA+SB60+3D-MPL(10μ)+QS21(5μ)
7.OspA+SB60+3D-MPL(30μ)+QS21(15μ)并且在第一次接种之后7天以及在第二次接种之后7天(在0天和14天接种)研究抗体效价和亚型。
在图3和图4中以图形式描述结果，并且证明本发明的制剂诱导出高水平的抗体并且它们优先的是IgG2a亚型。
                        实施例7
a)HSV-2 ICP27
在0天和14天时在后脚爪用各种NS1-ICP27制剂给雌性Balb/c小鼠免疫接种。每次注射含有5μg的NS1-ICP27以及SB26水包油乳液，QS21(10μg)和MPL(25μg)的组合物。在28天时取出腘淋巴结细胞并在体外用转染了ICP27基因的同系P815细胞进行刺激。用转染了ICP27和P815 ICP27阴性对照的P815靶细胞检测该培养物的特定的细胞溶解活性。
对于不同的免疫接种组以不同的效应子∶靶(E∶T)比例的具体裂解结果如下所示：ICP 27(5μg)E∶T    P815  转染了ICP27克隆121的P815100∶1  -1         030∶1   -2         -310∶1   3          03∶1    1          01∶1    2          20.3∶1  2          2ICP 27(5μg)+MPL(25μg)E∶T    P815  转染了ICP27克隆121的P815100∶1   5      730∶1    2      210∶1    1      23∶1     -1     -11∶1     -2     -20.3∶1   -4     -1ICP 27(5μg)+QS21(10μg)E∶T     P815  转染了ICP27克隆121的P815100∶1    4      1730∶1     5      1010∶1     3      73∶1      4      51∶1      3      50.3∶1    0      1ICP 27(5μg)+SB26E∶T     P815  转染了ICP27克隆121的P815100∶1    5        2030∶1     1        1910∶1     2        123∶1      -2       71∶1      1        50.3∶1    1        2ICP 27(5μg)+MPL(25μg)+QS21(10μg)E∶T     P815  转染了ICP27克隆121的P815100∶1    4          1330∶1     5          1210∶1     4          173∶1      1          31∶1      0          30.∶1     -1         -2ICP 27(5μg)+MPL(25μg)+QS21(10μg)+SB26E∶T      P815  转染了ICP27克隆121的P815100∶1      2          2030∶1       0          1710∶1       3          193∶1        3          81∶1        1          60.3∶1      2          3
在免疫接种组中获得的低ICP27特异性裂解％ICP 27(5μg)+QS21(10μg)ICP 27(5μg)+SB26ICP 27(5μg)+MPL(25μg)+QS21(10μg)ICP 27(5μg)+MPL(25μg)+QS21(10μg)+SB26而ICP 27(5μg)ICP 27(5μg)+MPL(25μg)是阴性
因此这些数据显示由重组NS1-ICP27在单独的水包油乳液或与QS21和MPL一起；或与QS21一起诱导出CTL。
b)用不同疫苗(NS1-ICP27/NS1-ICP27 MPL+QS21/NS1-ICP27 SB26＝MPL和QS21/仅佐剂)在脚爪处给5个Balb/c小鼠为一组的各组免疫接种。一个剂量含有10μg NS1-ICP27，10μg MPL和10μg QS21。在0天和7天进行两次免疫接种。在14天用5.2×103TCID50的HSV2菌株MS攻击小鼠。一直到攻击后14天都记录是否出现带状疱疹样的损伤和死亡。
在大肠杆菌中表达出了与流感病毒NS1片段的融合蛋白形式的HSV2的ICP27。在鼠带状疱疹样模型中对该纯化重组蛋白与MPLQS21制剂的组合物的保护效率进行评估。在用与MPL+QS21或与水包油乳液(SB26)+MPL和QS21组合的NS1-ICP27进行两次免疫接种的Balb/c小鼠可完全抵抗疾病(无带状疱疹样损伤)以及在HSV2野生型攻击之后没有死亡发出。相反，在单独用NS1-ICP27或用NS1-ICP27与SB26但没有MPL和QS21进行相组合的疫苗对小鼠进行免疫接种后没有观察到保护作用。
                               表1
                               两倍浓缩的载体
乳液SB 生育酚％ 角鲨烯％ 吐温80％     Span 85％     卵磷脂％     大小
    2626.163646162     555555     555555     0.40.40.60.812     000000     00.10000     500nm 90-100％800nm 10-0％500nm500nm500nm250-300nm180nm
    4040.1606566     55555     55555     0.40.410.40.4     1111.52     00.1000     500nm 80-100％800nm 20-0％500nm300nm500nm500nm
                                     表2
            HIVgp120W61D/                        鼠免疫原性(94243)/BALB/C(F.P.)
    组号     免疫原(剂量)/制剂 ELISA效价(第二次接种后7天)     ％IgG1    ％IgG2a    ％IgG2b
    123456789111213141516171819202122     gP120 10μggp120 10μg+3D-MPL 5μggP120 10μg+QS215μggp120 10μg+3D-MPL+QS21gP120 10μg/SB26gP120 10μg/SB26+3D-MPLgP120 10μg/SB26+QS21gP120 10μg/SB26+3D-MPL+QS21SB26+3D-MPL+QS21/gP120 10μggP120 10μg/SB62gp120 10μg/SB62+3D-MPL+QS21gP120 10μg/SB40gP120 10μg/SB40+3D-MPLgP120 10μg/SB40+QS21gP120 10μg/SB40+3D-MPL+QS21gP120 10μg/SB61gP120 10μg/SB61+3D-MPLgP120 10μg/SB61+QS21gP120 10μg/SB61+3D-MPL+QS21gP120 5μg/SB26gP120 5μg/SB26+3D-MPL+QS21     4944164215155274912205873885102017816918570410348217393632028521948953209217＜5077515407375967325089242736     1005489229431732322925490317814-3174299918     0154602421557608377441567-501357061     03281842713211909425718-191314121
由LINEST计算出的gp120W61D的ELISA效价：5个单体效价的几何平均值
                                    表3
                    基于3D-MPL的制剂；HIV工程猴研究
    读数     GMT ELisa W61 D     GMT Neut.MN 体内DTH 体外CMI
    制剂     P11     P111     P11     P111     LP IL-2     γIFN
    gp120(100μg)/油/水+MPL+QS21gp120(20μg)/由/水+MPL+QS21豚鼠中“过去的”gp120(100μg)/油/水+MPL     6052352026     934105015020064     1∶5001∶500   ＞1∶32001∶2400     ++ 没有检测没有检测

Claims (13)

1、一种疫苗组合物，包含有一种抗原和/或抗原组合物，QS21，3脱氧酰基化单磷酰脂A(3D-MPL)和水包油乳液，其中该水包油乳液具有下列组分：一种可代谢油，例如角鲨烯，α-生育酚和吐温80。
2、按照权利要求1中所述疫苗，其中QS21∶3D-MPL的比例是从1∶10到10∶1。
3、按照权利要求1或2所述疫苗组合物，能够在哺乳动物中激发针对该抗原或抗原组合物的细胞溶解性T细胞应答。
4、按照权利要求1-3任一项所述的疫苗组合物，它能够刺激干扰素γ的产生。
5、按照权利要求1-4任一项所述疫苗组合物，其中QS21∶3D-MPL的比例是从1∶1到1∶2.5。
6、如本文所述的一种疫苗组合物，其中包括来源于人免疫缺陷病毒、猫免疫缺陷病毒、单纯性疱疹病毒1型、单纯性疱疹病毒2型、人巨细胞病毒、甲、乙、丙或戊型肝炎病毒、呼吸道合胞体病毒、人乳头瘤病毒、流感病毒、沙门氏菌、萘瑟氏菌、螺旋体、衣原体、博德持氏菌、疟原虫或弓形体中的任何抗原或抗原组合物。
7、根据权利要求1-5任一项所述的疫苗，其中该抗原是肿瘤抗原。
8、权利要求1-5任一项所述组合物的应用，用于制造病毒，细菌或寄生虫感染的预防治疗的疫苗。
9、权利要求1-5任一项所述组合物的应用，用于制造病毒，细菌或寄生虫感染或癌症的免疫治疗的疫苗。
10、一种治疗患有或易于患病原体感染的哺乳动物的方法，包括施用一种安全和有效量的权利要求1-5任一项所述的组合物。
11、治疗患有癌症的哺乳动物的方法，该方法包括施用根据权利要求1-5任一项所述的安全和有效量的组合物。
12、一种制备权利要求1-5所述疫苗组合物的方法，包括将QS21，3D-MPL和如权利要求1中定义的水包油乳液与一种抗原或抗原组合物进行混合。
13、一种疫苗组合物，包括与水包油乳液相组合的一种抗原或抗原组合物，该乳液包括一种可代谢的油，α-生育酚以及吐温80。
CN94194554A 1993-12-23 1994-12-20 疫苗 Expired - Fee Related CN1086589C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939326253A GB9326253D0 (en) 1993-12-23 1993-12-23 Vaccines
GB9326253.3 1993-12-23

Publications (2)

Publication Number Publication Date
CN1138298A true CN1138298A (zh) 1996-12-18
CN1086589C CN1086589C (zh) 2002-06-26

Family

ID=10747069

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194554A Expired - Fee Related CN1086589C (zh) 1993-12-23 1994-12-20 疫苗

Country Status (23)

Country Link
US (5) US6146632A (zh)
EP (4) EP0868918B1 (zh)
JP (3) JP4125781B2 (zh)
KR (1) KR100350965B1 (zh)
CN (1) CN1086589C (zh)
AT (3) ATE177322T1 (zh)
AU (3) AU1316495A (zh)
CA (1) CA2179779C (zh)
CY (2) CY2530B1 (zh)
DE (5) DE69434956T2 (zh)
DK (3) DK0868918T3 (zh)
ES (3) ES2129801T3 (zh)
GB (1) GB9326253D0 (zh)
GR (1) GR3029750T3 (zh)
HK (3) HK1057991A1 (zh)
LU (2) LU91485I2 (zh)
NL (2) NL300362I1 (zh)
NZ (2) NZ329661A (zh)
PT (2) PT1327451E (zh)
SG (2) SG49257A1 (zh)
SI (3) SI0735898T1 (zh)
WO (2) WO1995017209A1 (zh)
ZA (1) ZA9410176B (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325117C (zh) * 1999-09-07 2007-07-11 史密丝克莱恩比彻姆生物有限公司 联合疫苗组合物
CN100346829C (zh) * 2000-10-18 2007-11-07 葛兰素史密丝克莱恩生物有限公司 包含免疫刺激性寡核苷酸和母育酚的佐剂组合物
CN102395600A (zh) * 2009-02-17 2012-03-28 葛兰素史密斯克莱生物公司 含有无铝佐剂的灭活的登革热病毒疫苗
CN101180076B (zh) * 2005-03-23 2012-10-24 葛兰素史密丝克莱恩生物有限公司 流感病毒及水包油乳液佐剂在制备诱导cd-4 t细胞和/或改善的b-记忆细胞应答的免疫原性组合物中的用途

Families Citing this family (559)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
WO1999010008A1 (en) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1009382B1 (en) * 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
ATE339223T1 (de) * 1998-03-09 2006-10-15 Glaxosmithkline Biolog Sa Kombinierte impfstoffzusammensetzungen
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
GB9806095D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
IL138809A0 (en) 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
CA2330610A1 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP2272859B1 (en) 1998-08-07 2014-10-22 University of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
KR100629028B1 (ko) * 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
EP2374889A3 (en) 1998-12-08 2012-02-22 GlaxoSmithKline Biologicals SA Novel compounds
KR100829407B1 (ko) 1998-12-08 2008-05-15 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) * 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
ES2347428T3 (es) * 1999-02-01 2010-10-29 EISAI R&D MANAGEMENT CO., LTD. Compuestos coadyuvantes inmunologicos.
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
GB2348132B (en) * 1999-03-02 2004-08-04 Nedaa Abdul-Ghani Nasif Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
ES2273670T3 (es) 1999-03-11 2007-05-16 Glaxosmithkline Biologicals S.A. Usos de polinucleotidos y polipeptidos casb618.
ATE451461T1 (de) 1999-03-12 2009-12-15 Glaxosmithkline Biolog Sa Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
AR022963A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
HUP0202930A2 (en) * 1999-03-26 2002-12-28 Smithkline Beecham Biolog Novel compounds
IL145731A0 (en) 1999-04-02 2002-07-25 Corixa Corp A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
JP4974414B2 (ja) * 1999-05-13 2012-07-11 ワイス・ホールディングズ・コーポレイション アジュバント混合製剤
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DE60143425D1 (de) * 2000-02-23 2010-12-23 Smithkline Beecham Biolog Neue verbindungen
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001078777A2 (en) * 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
EP2192128A3 (en) 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2001268472A1 (en) * 2000-06-16 2002-01-02 Smith Kline Beecham Corporation Icp27-binding polynucleotides
JP5139618B2 (ja) 2000-06-20 2013-02-06 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
JP4230765B2 (ja) 2000-07-31 2009-02-25 エーザイ株式会社 免疫アジュバント化合物、組成物、およびその使用方法
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20050019340A1 (en) 2000-10-18 2005-01-27 Nathalie Garcon Vaccines
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
EP2277895B1 (en) 2000-10-27 2013-08-14 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
JP2005510489A (ja) * 2000-11-16 2005-04-21 ユニバーシティ オブ メリーランド，ボルチモア 再発性のウイルス性疾患の予防
AU2002220018A1 (en) 2000-11-29 2002-06-11 Colorado State University System for in-vitro fertilization with spermatozoa separated into x-chromosome and y-chromosome bearing populations
EP2336368A1 (en) 2000-12-07 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
WO2003004525A2 (en) * 2001-01-26 2003-01-16 Walter Reed Army Institute Of Research Isolation and purification of plasmodium falciparum merozoite protein-142
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP5208347B2 (ja) 2001-02-23 2013-06-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002354644C1 (en) 2001-07-10 2009-04-30 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
EP1420818B1 (en) * 2001-07-26 2018-11-21 Otago Innovation Limited Antigenic compositions
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
ES2368907T3 (es) 2002-04-19 2011-11-23 The Governing Council Of The University Of Toronto Procedimientos y composiciones inmunológicas para el tratamiento de la enfermedad de alzheimer.
ATE545651T1 (de) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic Vektoren zur expression von hml-2-polypeptiden
EP2011510B1 (en) 2002-07-18 2011-01-12 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
US20060034854A1 (en) 2002-08-02 2006-02-16 Berthet Francois-Xavier J Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7169548B2 (en) 2002-09-13 2007-01-30 Xy, Inc. Sperm cell processing and preservation systems
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
NZ539509A (en) 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP1998177A3 (en) 2003-01-06 2009-02-18 Wyeth Compositions and methods for diagnosing and treating colon cancers
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
DE602004024874D1 (de) 2003-03-28 2010-02-11 Inguran Llc Eschlechts-sortierten tierspermien
JP2006522090A (ja) 2003-04-04 2006-09-28 ファイザー・プロダクツ・インク マイクロ流動化された水中油形エマルジョン及びワクチン組成物
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
CA2885040C (en) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
US8574596B2 (en) 2003-10-02 2013-11-05 Glaxosmithkline Biologicals, S.A. Pertussis antigens and use thereof in vaccination
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1730182B1 (en) 2004-02-05 2015-04-29 The Ohio State University Research Foundation Chimeric vegf peptides
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
JP5041279B2 (ja) * 2004-04-22 2012-10-03 株式会社 Ｍｂｒ 細菌細胞壁骨格成分を含有する製剤
PL1740217T3 (pl) 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
ES2647491T3 (es) 2004-05-21 2017-12-21 Novartis Vaccines And Diagnostics, Inc. Vectores del alfavirus para las vacunas del virus de la gripe
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
DE602005025342D1 (de) * 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US8085126B2 (en) * 2004-07-27 2011-12-27 Honeywell International Inc. Identification with RFID asset locator for entry authorization
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
KR101508563B1 (ko) 2004-09-22 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
CA2590974C (en) 2005-01-27 2017-10-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
CA2601022C (en) * 2005-03-23 2023-03-07 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
SG158145A1 (en) 2005-03-31 2010-01-29 Glaxosmithkline Biolog Sa Vaccines against chlamydial infection
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CA2605749C (en) * 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
EP2457926B1 (en) 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
JP5222134B2 (ja) 2005-06-15 2013-06-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Ｈｅｒ−２ペプチド
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
US20070078376A1 (en) * 2005-09-30 2007-04-05 Smith Gregory A Functionalized microneedles transdermal drug delivery systems, devices, and methods
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
KR20080066712A (ko) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
KR20080080087A (ko) * 2005-09-30 2008-09-02 티티아이 엘뷰 가부시키가이샤 신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2377551A3 (en) * 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ568210A (en) * 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CA2630218A1 (en) * 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
WO2007061781A1 (en) * 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2816182C (en) 2005-12-22 2018-02-20 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
WO2007079190A2 (en) * 2005-12-29 2007-07-12 Tti Ellebeau, Inc. Device and method for enhancing immune response by electrical stimulation
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
ES2619160T7 (es) 2006-01-27 2020-07-29 Seqirus Uk Ltd Vacunas contra la gripe que contienen hemaglutinina y proteínas de la matriz
ES2388556T3 (es) 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US20070243212A1 (en) 2006-03-30 2007-10-18 Embrex, Inc. Methods and compositions for vaccination of poultry
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2390359A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the ICOS gene
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2654709A1 (en) 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
CN105727276A (zh) 2006-07-17 2016-07-06 葛兰素史密丝克莱恩生物有限公司 流感疫苗
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
AU2007276217B2 (en) 2006-07-18 2013-08-29 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
WO2008025095A1 (en) * 2006-09-01 2008-03-06 Csl Limited Method of eliciting or inducing an immune response
EP2066344B2 (en) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
EP2433648A3 (en) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EA200900784A1 (ru) 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
MX2009010800A (es) 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
PL2185191T3 (pl) 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101795709B (zh) 2007-08-02 2013-07-17 彼昂德瓦克斯医药有限公司 多亚基多表位流感疫苗
WO2009020553A2 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2009034473A2 (en) 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
US9050280B2 (en) 2007-09-17 2015-06-09 Mdxhealth Sa Methylation detection of MGMT
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
CA2707247A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
WO2009076158A1 (en) * 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
RU2498994C2 (ru) 2007-12-21 2013-11-20 Новартис Аг Мутантные формы стрептолизина о
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
WO2009126816A1 (en) * 2008-04-09 2009-10-15 Ventria Bioscience Production of ospa for lyme disease control
MX2010011412A (es) 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vacuna.
US9527906B2 (en) 2008-04-18 2016-12-27 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2733356C (en) * 2008-08-01 2016-06-07 Gamma Vaccines Pty Limited Influenza vaccines
ES2761697T3 (es) 2008-08-28 2020-05-20 Novartis Ag Proceso para preparar una emulsión de aceite en agua que contiene escualeno procedente de levaduras
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
US20100092526A1 (en) 2008-09-26 2010-04-15 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
EP2356225A1 (en) 2008-12-03 2011-08-17 Protea Vaccine Technologies Ltd. GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
ES2622562T3 (es) 2008-12-09 2017-07-06 Pfizer Vaccines Llc Vacuna de péptido CH3 de IgE
CN102257135B (zh) 2008-12-16 2017-06-09 纳米医疗公司 流感疫苗的生产
CN103897045A (zh) 2009-01-12 2014-07-02 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
CN102575284A (zh) 2009-03-17 2012-07-11 MDx健康公司 改进的基因表达检测
EP2510947B1 (en) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
RU2536248C2 (ru) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Пневмококковая вакцина и ее применения
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
MA33409B1 (fr) 2009-05-27 2012-07-03 Glaxosmithkline Biolog Sa Produits de recombinaisoon de casb7439
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
JP2012532600A (ja) 2009-07-07 2012-12-20 ノバルティス アーゲー 保存された大腸菌免疫原
CN105214080A (zh) 2009-07-15 2016-01-06 诺华股份有限公司 Rsv f蛋白组合物和其制作方法
PL2464658T3 (pl) 2009-07-16 2015-03-31 Novartis Ag Immunogeny z Escherichia coli o zniesionej toksyczności
KR101435953B1 (ko) 2009-07-17 2014-09-02 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN104650241A (zh) 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
PE20161551A1 (es) 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
KR101746880B1 (ko) * 2009-09-10 2017-06-14 메리얼 인코포레이티드 사포닌-함유 면역보강제를 포함하는 신규 백신 제형
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
JP5872472B2 (ja) 2009-10-09 2016-03-01 シービオ・リミティッド シャペロニン１０変異体
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US20110159031A1 (en) 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
CA2785585A1 (en) 2009-12-22 2011-06-30 Celldex Therapeutics, Inc. Vaccine compositions
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
BR112012022939A2 (pt) 2010-03-11 2016-08-02 Immune Design Corp composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
JP2013523617A (ja) 2010-03-26 2013-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｉｖワクチン
US9827300B2 (en) 2010-03-30 2017-11-28 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
BR112012025364A2 (pt) 2010-04-07 2015-09-22 Novartis Ag método para geração de partícula semelhante a vírus de parvovírus b19
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
ES2614807T3 (es) 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
JP2014501225A (ja) 2010-09-27 2014-01-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2637687B1 (en) 2010-11-08 2021-01-06 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP2667892B1 (en) 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Rsv immunization regimen
AU2012211043B2 (en) 2011-01-27 2017-04-06 Gamma Vaccines Pty Limited Combination vaccines
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
US9321813B2 (en) 2011-03-29 2016-04-26 Uab Research Foundation Methods and compositions for cytomegalovirus IL-10 protein
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
PT3275892T (pt) 2011-05-13 2020-04-08 Glaxosmithkline Biologicals Sa Antigénios f de rsv de pré-fusão
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
EP2717909B1 (en) 2011-06-04 2017-12-06 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2013006569A2 (en) * 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
ES2687129T3 (es) 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CA2845872C (en) 2011-08-22 2023-03-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
WO2013036907A1 (en) 2011-09-09 2013-03-14 Nanobio Corporation Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine
CN103930436A (zh) 2011-09-14 2014-07-16 诺华股份有限公司 大肠杆菌疫苗组合
EP2755683B1 (en) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
CA2848611A1 (en) 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
JP6121436B2 (ja) 2011-11-23 2017-04-26 バイオベン・3・リミテッドBioven 3 Limited 組換えタンパク質及びそれらの治療的用途
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
BR112014013876A2 (pt) 2011-12-08 2019-09-24 Novartis Ag vacina à base de toxina de clostridium difficile
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
EP2817320A1 (en) 2012-02-24 2014-12-31 Novartis AG Pilus proteins and compositions
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
NZ714625A (en) 2012-03-23 2017-02-24 Pitney Pharmaceuticals Pty Ltd Kinase inhibitors for the treatment of cancer
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
BR112014024612A2 (pt) 2012-04-02 2021-06-08 Univ North Carolina Chapel Hill ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
RU2727476C2 (ru) 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
MX350274B (es) 2012-05-16 2017-08-31 Immune Design Corp Vacunas para hsv-2.
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
CA2875683A1 (en) 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2877208B1 (en) 2012-07-24 2021-05-12 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
PE20150356A1 (es) 2012-07-24 2015-03-20 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
US9480738B2 (en) 2012-08-01 2016-11-01 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
JP2015525784A (ja) 2012-08-03 2015-09-07 インフェクティアス ディジーズ リサーチ インスティチュート 活動性結核菌感染を治療するための組成物及び方法
EP2880014B1 (en) 2012-08-06 2017-05-17 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
JP2014040396A (ja) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute 脂質異常症治療薬を含有するアジュバント組成物
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
EA201590427A1 (ru) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
SG11201500978TA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic compositions
ES2854754T3 (es) 2012-10-24 2021-09-22 Platelet Targeted Therapeutics Llc Tratamiento dirigido a plaquetas
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
DK2925355T3 (en) 2012-11-30 2018-01-15 Glaxosmithkline Biologicals Sa PSEUDOMONAS ANTIGENES AND ANTIGEN COMBINATIONS
WO2014086787A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
KR102255753B1 (ko) 2012-12-17 2021-05-26 뉴사우스 이노베이션즈 피티와이 리미티드 뮤신 관련 질환의 치료
EP3446708A1 (en) 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
RU2747857C2 (ru) 2013-03-15 2021-05-17 Ин3Био Лтд. Самособирающиеся синтетические белки
BR112015024860B1 (pt) 2013-03-28 2023-11-07 Access To Advanced Health Institute Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
EP2994162B1 (en) * 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
CA2909586C (en) 2013-05-15 2021-08-31 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN110734500A (zh) 2013-06-26 2020-01-31 北卡罗来纳-查佩尔山大学 用于登革病毒疫苗的方法与组合物
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US9975925B2 (en) 2013-08-28 2018-05-22 Glaxosmithkline Biologicals S.A. Influenza antigens and antibodies
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10208102B2 (en) 2013-11-01 2019-02-19 University Of Oslo Albumin variants and uses thereof
CA2929126C (en) 2013-11-13 2020-01-07 University Of Oslo Outer membrane vesicles and uses thereof
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
CA2931112A1 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
CN106163551A (zh) 2013-12-31 2016-11-23 传染性疾病研究院 单瓶疫苗制剂
US9868769B2 (en) 2014-01-06 2018-01-16 The United States Of America, As Represented By The Secretary Of Agriculture Mutated Salmonella enteriaca
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN114887048A (zh) 2014-01-21 2022-08-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2015112485A1 (en) 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
EP3125931A4 (en) 2014-04-03 2017-09-20 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
NZ766003A (en) 2014-07-23 2024-01-26 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
ES2924988T3 (es) 2014-10-10 2022-10-13 Univ Michigan Regents Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
EP3212672A4 (en) 2014-11-02 2018-04-25 The University of North Carolina at Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US20170281744A1 (en) 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
BR112017013891B1 (pt) 2015-01-15 2024-01-30 Pfizer Inc Composições imunogênicas para uso em vacinas pneumocócicas
WO2016134300A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
CN116603058A (zh) 2015-03-26 2023-08-18 Gpn疫苗有限公司 链球菌疫苗
BR112017025316A2 (pt) 2015-05-26 2018-07-31 Ohio State Innovation Foundation estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
WO2017013548A1 (en) 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PE20181322A1 (es) 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
ES2607715B1 (es) 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
TWI654302B (zh) 2016-01-19 2019-03-21 輝瑞股份有限公司 癌症疫苗
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
CN109562154A (zh) 2016-03-10 2019-04-02 爱普瑞希斯有限公司 带有修饰hsp70域的抗原结合融合蛋白
KR20180127320A (ko) 2016-03-14 2018-11-28 유니버시티에트 이 오슬로 변경된 FcRn 결합을 갖는 조작된 면역글로불린
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
KR102392974B1 (ko) 2016-05-16 2022-05-02 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Tlr 작용제를 함유하는 제제 및 사용 방법
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
EP3458088A2 (en) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
MX2019003035A (es) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
MA47265A (fr) 2017-01-13 2019-11-20 Agenus Inc Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers
HRP20220573T1 (hr) 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
WO2018176103A1 (en) 2017-03-30 2018-10-04 The University Of Queensland "chimeric molecules and uses thereof"
JP2020515587A (ja) 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 免疫原性組成物、使用及び処置方法
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
HUE062927T2 (hu) 2017-05-01 2023-12-28 Agenus Inc Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
AU2018283973A1 (en) 2017-06-11 2020-01-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CN111315362A (zh) 2017-06-15 2020-06-19 传染病研究所 纳米结构脂质载剂和稳定乳剂以及其用途
WO2019016597A2 (en) 2017-07-18 2019-01-24 Bioven 3 Limited SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
EP3641808A1 (en) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
EP3679062A1 (en) 2017-09-04 2020-07-15 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
MY194449A (en) 2017-11-03 2022-11-30 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
US11702674B2 (en) 2018-06-12 2023-07-18 Glaxosmithkline Biologicals Sa Simian adenovirus vectors comprising the ChAd-157 fiber protein
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
JP2021534761A (ja) 2018-08-23 2021-12-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性タンパク質および組成物
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF
EP3890775A1 (en) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
JP2022528158A (ja) 2019-04-10 2022-06-08 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
US20220249646A1 (en) 2019-05-25 2022-08-11 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
MX2021015922A (es) 2019-06-25 2022-03-22 In3Bio Ltd Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos.
WO2021013798A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
BR112021026565A2 (pt) 2019-08-05 2022-05-03 Glaxosmithkline Biologicals Sa Composição imunogênica
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
EP3808765A1 (en) 2019-10-14 2021-04-21 ETH Zurich Cell line for tcr discovery and engineering and methods of use thereof
JP2021087420A (ja) 2019-11-01 2021-06-10 ファイザー・インク Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ組成物およびその方法
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
AU2021223184A1 (en) 2020-02-23 2022-08-18 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021205077A1 (en) 2020-04-09 2021-10-14 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
WO2022002783A1 (en) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
KR20230083271A (ko) 2020-08-17 2023-06-09 유니버시타트 바셀 암 치료에 사용하기 위한 lfa-1 신호전달 매개체
AU2021330836A1 (en) 2020-08-24 2023-05-04 Glaxosmithkline Biologicals Sa Covid-19 vaccines with tocopherol-containing squalene emulsion adjuvants
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
WO2022083768A1 (zh) 2020-10-23 2022-04-28 江苏省疾病预防控制中心(江苏省公共卫生研究院) 免疫原性组合物及其应用
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
US20220265805A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
JP2024510717A (ja) 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
EP4313137A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112023027401A2 (pt) 2021-06-28 2024-03-12 Glaxosmithkline Biologicals Sa Antígenos do vírus influenza
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0513861B1 (en) * 1987-11-03 1997-02-26 Syntex (U.S.A.) Inc. Vaccine adjuvant comprising a tetra-polyol
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69015222T2 (de) * 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
JP2502234B2 (ja) * 1990-06-29 1996-05-29 カイロン コーポレイション リポソ―ム含有ワクチン組成物
EP0550485A1 (en) * 1990-09-28 1993-07-14 SMITHKLINE BEECHAM BIOLOGICALS s.a. DERIVATIVES OF gp160 AND VACCINES BASED ON gp160 OR A DERIVATIVE THEREOF, CONTAINING AN ADJUVANT
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
RO116459B1 (ro) 1991-07-25 2001-02-28 Idec Pharma Corp Compozitie imunogena
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
UA40597C2 (uk) * 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
JP3734263B2 (ja) * 1993-05-25 2006-01-11 ワイス・ホールディングズ・コーポレイション 呼吸器シンシチウムウイルスに対するワクチンのためのアジュバント
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325117C (zh) * 1999-09-07 2007-07-11 史密丝克莱恩比彻姆生物有限公司 联合疫苗组合物
CN100346829C (zh) * 2000-10-18 2007-11-07 葛兰素史密丝克莱恩生物有限公司 包含免疫刺激性寡核苷酸和母育酚的佐剂组合物
CN101180076B (zh) * 2005-03-23 2012-10-24 葛兰素史密丝克莱恩生物有限公司 流感病毒及水包油乳液佐剂在制备诱导cd-4 t细胞和/或改善的b-记忆细胞应答的免疫原性组合物中的用途
CN102395600A (zh) * 2009-02-17 2012-03-28 葛兰素史密斯克莱生物公司 含有无铝佐剂的灭活的登革热病毒疫苗
CN102395600B (zh) * 2009-02-17 2015-03-25 葛兰素史密斯克莱生物公司 含有无铝佐剂的灭活的登革热病毒疫苗

Also Published As

Publication number Publication date
AU1316695A (en) 1995-07-10
EP0868918A3 (en) 2000-04-26
DE69417063T2 (de) 1999-10-28
EP1327451B1 (en) 2007-04-18
EP0868918B1 (en) 2004-04-28
PT1327451E (pt) 2007-07-23
CA2179779C (en) 2010-04-20
DK0735898T3 (da) 1999-08-23
US6623739B1 (en) 2003-09-23
CY2530B1 (en) 2006-04-12
AU6803298A (en) 1998-07-09
LU91485I2 (fr) 2008-12-15
US7510698B2 (en) 2009-03-31
LU91486I2 (fr) 2008-12-15
HK1057991A1 (en) 2004-04-30
CY2593B2 (en) 2009-11-04
DE69417063D1 (de) 1999-04-15
JP4126079B2 (ja) 2008-07-30
DE69433750D1 (de) 2004-06-03
ES2129801T3 (es) 1999-06-16
US20070134268A1 (en) 2007-06-14
EP0735898A1 (en) 1996-10-09
NZ329661A (en) 2005-03-24
NZ277802A (en) 1998-04-27
DE69433750T2 (de) 2005-08-04
SI1327451T1 (sl) 2007-08-31
SG49257A1 (en) 1998-05-18
CA2179779A1 (en) 1995-06-29
AU687494B2 (en) 1998-02-26
ATE265228T1 (de) 2004-05-15
HK1012243A1 (en) 1999-07-30
DK1327451T3 (da) 2007-08-20
US6146632A (en) 2000-11-14
NL300363I1 (nl) 2009-01-05
US20040043038A1 (en) 2004-03-04
US20060182753A1 (en) 2006-08-17
DE122008000055I1 (de) 2009-02-19
DE69434956T2 (de) 2008-01-17
AU705519B2 (en) 1999-05-27
ATE177322T1 (de) 1999-03-15
JP2006249080A (ja) 2006-09-21
WO1995017210A1 (en) 1995-06-29
EP0868918A2 (en) 1998-10-07
US7169391B2 (en) 2007-01-30
JP2007231029A (ja) 2007-09-13
ATE359818T1 (de) 2007-05-15
EP1792628A1 (en) 2007-06-06
ES2219837T3 (es) 2004-12-01
AU1316495A (en) 1995-07-10
WO1995017209A1 (en) 1995-06-29
SI0868918T1 (en) 2004-08-31
GR3029750T3 (en) 1999-06-30
JP4125781B2 (ja) 2008-07-30
ES2285036T3 (es) 2007-11-16
JP4126067B2 (ja) 2008-07-30
SG73578A1 (en) 2000-06-20
DK0868918T3 (da) 2004-08-16
PT868918E (pt) 2004-08-31
EP1327451A1 (en) 2003-07-16
JPH09506887A (ja) 1997-07-08
EP0735898B1 (en) 1999-03-10
ZA9410176B (en) 1995-11-17
KR100350965B1 (ko) 2003-02-25
NL300362I1 (nl) 2009-01-05
US7029678B2 (en) 2006-04-18
SI0735898T1 (en) 1999-06-30
CN1086589C (zh) 2002-06-26
HK1021504A1 (en) 2000-06-16
AU6803198A (en) 1998-07-09
AU705521B2 (en) 1999-05-27
DE122008000054I1 (de) 2009-02-19
DE69434956D1 (de) 2007-05-31
GB9326253D0 (en) 1994-02-23

Similar Documents

Publication Publication Date Title
CN1086589C (zh) 疫苗
CN1122530C (zh) 疫苗
CN1289065C (zh) 含有皂苷和固醇的疫苗
CN1091978A (zh) 粒细胞-巨噬细胞-集落刺激因子作为疫苗佐剂的用途
CN101043902A (zh) 针对丙型肝炎病毒的疫苗组合物
CN1434864A (zh) 增强对单纯疱疹病毒疫苗的免疫应答的方法
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine
Lu et al. Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles
CN1295480A (zh) 含有白细胞介素－12和呼吸道合胞病毒抗原的疫苗
AU687494C (en) Vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20020626

Termination date: 20101220